Performance of PFE Pfizer | -30.9% in 12m
Compare PFE with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Pfizer with its related Sector/Index XLV
Performance Duell PFE vs XLV
| TimeFrame | PFE | XLV |
|---|---|---|
| 1 Day | 0.55% | 0.03% |
| 1 Week | -2.31% | 0.73% |
| 1 Month | -7.94% | -3.99% |
| 3 Months | -7.54% | 0.86% |
| 6 Months | -16.1% | 12.64% |
| 12 Months | -30.9% | 8.01% |
| YTD | -13.3% | 1.21% |
| Rel. Perf. 1m | -0.33 | |
| Rel. Perf. 3m | -1.59 | |
| Rel. Perf. 6m | -2.60 | |
| Rel. Perf. 12m | -4.41 |
Is Pfizer a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Pfizer is currently (April 2024)
neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -18.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PFE as of April 2024 is 22.12. This means that PFE is currently overvalued and has a potential downside of -12.91% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PFE as of April 2024 is 22.12. This means that PFE is currently overvalued and has a potential downside of -12.91% (Sold with Premium).
Is PFE a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 15
- Sell: 0
- Strong Sell: 0
Values above 0%: PFE is performing better - Values below 0%: PFE is underperforming
Compare PFE with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -4.96% | -5.91% | -40.22% | -58.38% |
| US NASDAQ 100 | QQQ | -6.25% | -5.16% | -42.04% | -69.98% |
| US Dow Jones Industrial 30 | DIA | -2.97% | -5.31% | -33.85% | -47.91% |
| German DAX 40 | DBXD | -4.65% | -6.59% | -39.18% | -45.13% |
| UK FTSE 100 | ISFU | -5.82% | -9.49% | -31.87% | -38.37% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -3.22% | -9.26% | -18.62% | -19.07% |
| Hongkong Hang Seng | HSI | -11.02% | -9.92% | -14.43% | -12.39% |
| Japan Nikkei 225 | EXX7 | -2.24% | 0.07% | -33.22% | -48.65% |
| India NIFTY 50 | INDA | -4.24% | -11.01% | -38.58% | -61.06% |
| Brasil Bovespa | EWZ | -4.91% | -5.71% | -23.25% | -52.82% |
PFE Pfizer vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -3.12% | -6.39% | -43.31% | -74.91% |
| Consumer Discretionary | XLY | -5.93% | -4.41% | -35.44% | -54.24% |
| Consumer Staples | XLP | -3.85% | -8.10% | -29.81% | -32.99% |
| Energy | XLE | -3.12% | -11.40% | -28.52% | -49.44% |
| Financial | XLF | -3.40% | -6.54% | -44.69% | -59.65% |
| Health Care | XLV | -3.04% | -3.95% | -28.78% | -38.87% |
| Industrial | XLI | -4.13% | -6.90% | -43.29% | -59.28% |
| Materials | XLB | -2.94% | -5.96% | -36.80% | -47.17% |
| Real Estate | XLRE | -3.93% | -3.11% | -29.00% | -34.48% |
| Technology | XLK | -6.10% | -4.17% | -41.37% | -68.74% |
| Utilities | XLU | -3.47% | -12.29% | -28.68% | -31.16% |
| Aerospace & Defense | XAR | -5.24% | -6.19% | -35.94% | -52.85% |
| Biotech | XBI | -3.11% | 1.99% | -42.32% | -36.10% |
| Homebuilder | XHB | -5.86% | -2.81% | -64.91% | -85.60% |
| Retail | XRT | -5.19% | -3.23% | -41.92% | -53.23% |
Does Pfizer outperform its market, is PFE a Sector Leader?
No, over the last 12 months Pfizer (PFE) made -30.86%, while its related Sector, the Health Care Sector SPDR Fund (XLV) made 8.01%.
Over the last 3 months PFE made -7.54%, while XLV made 0.86%.
No, over the last 12 months Pfizer (PFE) made -30.86%, while its related Sector, the Health Care Sector SPDR Fund (XLV) made 8.01%.
Over the last 3 months PFE made -7.54%, while XLV made 0.86%.
| Period | PFE | XLV | S&P 500 |
|---|---|---|---|
| 1 Month | -7.94% | -3.99% | -2.03% |
| 3 Months | -7.54% | 0.86% | 4.60% |
| 12 Months | -30.86% | 8.01% | 27.52% |